REG - Roquefort Theraptcs. - Notice of Admission

Roquefort TherapeuticsAnnouncement

15/09/2022 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220915:nRSO6340Za&default-theme=true

RNS Number : 6340Z  Roquefort Therapeutics PLC  15 September 2022

 

15 September 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Notice of Admission

 

Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech
company focused on developing first in class drugs in the high value and high
growth oncology segment, confirms that application has been made to the
Financial Conduct Authority and the London Stock Exchange for a total of
57,249,998 new Ordinary Shares, comprising 50,000,000 Consideration Shares and
7,249,998 Placing Shares of £0.01 each, to the Official List of the UKLA by
way of a standard listing under Chapter 14 of the UKLA's Listing Rules and to
trading on the London Stock Exchange's main market for listed securities
("Admission"). Admission will take place at 8:00a.m. tomorrow.

 

Completion of the Acquisition and the Placing will become effective on
Admission.

 

Capitalised terms used in this announcement (unless otherwise defined) carry
the same meanings as those ascribed to them in the Company's Prospectus dated
13 September 2022, unless the context requires otherwise.

 

The Prospectus and further information on the Company can be found on
Roquefort Therapeutic's website at: https://www.roquefortplc.com
(https://www.roquefortplc.com)

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Regulation (EU) No 596/2014 which is part of UK law by
virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon
the publication of this announcement via a Regulatory Information Service,
this inside information is now considered to be in the public domain.

 

-Ends-

 

 
Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Hybridan LLP (Joint Broker)

 Claire Louise Noyce                        +44 (0)203 764 2341

 Optiva Securities Limited (Joint Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 

 

LEI: ‎254900P4SISIWOR9RH34

 

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech
company developing first in class drugs in the high value and high growth
oncology segment prior to partnering or selling to big pharma.

 

Since listing in March 2021, Roquefort Therapeutics has successfully acquired
Lyramid Pty Limited, a leader in the development of medicines for a new
therapeutic target, Midkine (a human growth factor associated with cancer
progression), and most recently acquired Oncogeni Ltd, founded by Nobel
Laureate Professor Sir Martin Evans, which has developed two families of
innovative cell and RNA oncology medicines.

 

Roquefort Therapeutics' portfolio consists of four fully funded, novel
patent-protected pre-clinical anti-cancer medicines.  The highly
complementary profile of four best-in-class medicines consists of:

·    Midkine antibodies with significant in vivo efficacy and toxicology
studies;

·    Midkine RNA therapeutics with novel anti-cancer gene editing action;

·    MK cell therapy with direct and NK-mediated anti-cancer action; and

·    siRNA targeting novel STAT-6 target in solid tumours showing
significant in vivo efficacy.

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSEAFNSFALAEFA